The effects of recreational cannabis legalization on the medical cannabis market
Recreational cannabis legalization is coming (almost) always follows that of medical cannabis, often a few years later. However, it has a disruptive effect on the medical cannabis market. Since the two markets serve entirely different purposes and operate in entirely different ways—yet both focus on the same product—their overlap creates problems, especially for patients.
A Shift from Medical to Recreational Use
The medical and recreational cannabis markets are aimed at different audiences and are governed by different regulations and taxes. However, the products are similar, and it is tempting for patients and retailers to switch between the two. From the patients’ perspective, the legalization of recreational cannabis allows them to obtain supplies at any time without having to see a doctor. From the retailers’ perspective, selling recreational cannabis is more profitable because market prices are higher.
Among the 10 U.S. states (soon to be 11) that have both medical and recreational cannabis markets; four of them have markets that are established enough to assess the effects of recreational cannabis legalization on the medical cannabis market. These are Oregon, Nevada, Colorado, and Alaska. An analysis of The Associated Press shows that in these four states, the number of medical cannabis patients dropped after recreational use was legalized: from approximately 66% in Oregon, 63% in Alaska, 40% in Nevada, and 19% in Colorado.
An unspecified portion of this shift stems from the fact that many medical cannabis «patients» were actually recreational users. In fact, some people sometimes claim to have pain or a headache in order to obtain a medical cannabis card and gain legal access to cannabis. According to the anti-legalization organization Smart Approaches to Marijuana, 80% for Americans applying for a card do not have cancer, Parkinson’s, or glaucoma—conditions for which the use of medical cannabis is scientifically proven, according to the association. In California, it was particularly easy to obtain a card before legalization; a simple video consultation with a doctor was sufficient, a practice sometimes facilitated by companies.
The problem is that, following this shift, market forces come into play and the specialized supply of medical cannabis is gradually disappearing. Patients are therefore left with fewer options and higher prices, since recreational cannabis is often taxed much more heavily than medical cannabis. In Oregon, for example, after losing nearly two-thirds of their patients, the number of medical cannabis dispensaries has dropped from 400 to just 2. Patients with specific needs—such as a particular strain, for example—are being left behind.
The unintended consequences of this transfer
With the closure of medical cannabis dispensaries, patients have begun to face supply issues. «Patients have needs. Consumers have desires,» explains Anthony Taylor, a member of the Oregon Cannabis Commission. «Patients are in crisis right now.» State lawmakers are working on a bill that would allow home delivery of medical cannabis to reach patients in rural areas.
Another unintended consequence of this market shift relates to prices. As Robin Beverett, a veteran with PTSD who moved from Texas to California to gain access to medical cannabis, explains, prices have risen significantly since recreational cannabis sales began in 2018: Before, 3.5 grams of dried flower cost 35$; now, she says, prices are around 100$. «It’s ridiculous. The prices are astronomical. Going to a dispensary is just out of the question if you’re on an average income.».
High taxes on recreational cannabis products make it more difficult for patients with regular cannabis needs to access the product. Oregon has enacted a law allowing patients to purchase medical cannabis at recreational cannabis stores without paying taxes. These stores are therefore permitted to sell medical cannabis, but it accounts for only 8.5% of their sales. In Canada, on the other hand, since legalization, medical cannabis is subject to the same excise tax as recreational cannabis and the shortages affecting the recreational market also affect patients who use cannabis for medical purposes.
-
Cannabis in Europe3 weeks ago
Bosnia and Herzegovina Continues to Roll Out Medical Cannabis Following Its Legalization
-
Cannabis in France3 weeks ago
France Submits the Long-Awaited Decree on the Reimbursement of Medical Cannabis to the Council of State
-
Cannabis in Ireland4 weeks ago
The Irish Parliament recommends decriminalizing all drugs
-
Cannabis in the U.S.3 weeks ago
The DEA Begins Hearings on the Federal Rescheduling of Cannabis
-
Cannabis in Switzerland4 weeks ago
St. Gallen, Switzerland, Launches Its 8th Legal Cannabis Pilot Project
-
Cannabis in France4 weeks ago
Reunion Island: The CBD Cannabis Cup Returns to Jardin Maniron on August 16, 2026
-
Business2 weeks ago
China Invests $10 Million in Medical Cannabis in Lebanon
-
Cannabis in Thailand3 weeks ago
Thailand Threatens Cannabis Shops with Severe Penalties


You must be logged in to post a comment Login